Examples of Automated Databases

Stergachis, Andy; Saunders, Kathleen; Davis, Robert L.; Kimmel, Stephen E.; Schinnar, Rita; Chan, Kuang-Cheng; Shatin, Deborah; Rawson, Nigel S. B.; Hennessy, Sean; Downey, Winanne; Stang, MaryRose; Beck, Patricia; Osei, William; Leufkens, Hubert G.M.; MacDonald, Thomas M.; Gelfand, Joel M.

doi:10.1002/9781118707999.ch12

Cited by 12 publications

(9 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Electronic medical records are routinely used in UK general practice. GPs usually enter diagnosis and prescription information into the electronic medical records to assist them in patient management [18].…”

Section: Methodsmentioning

confidence: 99%

Unlicensed use of metformin in children and adolescents in the UK

Hsia

Dawoud

Sutcliffe

et al. 2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Metformin is licensed for type 2 diabetes mellitus (DM) treatment in the UK.• Evidence has shown the moderate efficacy of metformin treatment for polycystic ovarian syndrome (PCOS) and obesity. WHAT THIS STUDY ADDS• Metformin prescribing increased in children and adolescents between 2000 and 2010, in particular in girls aged 16-18 years.• PCOS and obesity were the main, but unlicensed, indications for metformin prescribing amongst female adolescents. AIMMetformin is the most commonly prescribed oral anti-diabetic drug in young people. It is also prescribed for polycystic ovarian syndrome (PCOS) and obesity treatment in adults in an unlicensed fashion. Little is known as to the extent metformin has been used in young people. We investigated the use of metformin in children and adolescents aged 0-18 years in the UK. METHODSPopulation-based prescribing data were obtained from the UK IMS Disease Analyzer between January 2000 and December 2010. RESULTSA total of 2674 metformin prescriptions were issued to 337 patients (80% female) between 2000 and 2010. The prevalence of metformin prescribing increased from 0.03 per 1000 person-years [95% confidence interval (CI) 0.02, 0.05] to 0.16 per 1000 person-years (95% CI 0.12, 0.20) (P = 0.001). There was a steady increase in metformin prescribing in girls aged 16-18 years. There were 290 metformin treated patients (81% female; n = 235) who had at least one diagnosis of diabetes, PCOS or obesity. Among these patients, PCOS was the most common indication for metformin prescribing in girls (n = 120) followed by diabetes. There were 22 patients (7.6%) who received metformin for obesity treatment only. CONCLUSIONSPrescribing of metformin increased between 2000 and 2010, in particular amongst girls aged 16-18 years. The main indication for metformin prescribing was PCOS. At present, metformin is not licensed for PCOS and obesity treatment in adults or children. As there is a steady increase in the prescribing of metformin in young people, further studies are required to investigate the efficacy and safety of these prescriptions.

show abstract

Section: Methodsmentioning

confidence: 99%

Unlicensed use of metformin in children and adolescents in the UK

Hsia

Dawoud

Sutcliffe

et al. 2011

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…This database has been shown to be representative of the Dutch population . An important advantage of this database is its virtually complete coverage of a relatively homogenous population of reasonable size …”

Section: Methodsmentioning

confidence: 99%

“…As reported by Sternogachis, in the Netherlands medical care including prescription medications is practically paid completely by a universal insurance system of public and private origins. This also results in healthcare of virtually uniform quality being provided to all citizens, regardless of their geographical location in this densely populated country.…”

Section: Methodsmentioning

confidence: 99%

Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study

Kröger

Marum

Souverein

et al. 2015

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

Among 3154 patients there were 657 UI cases during a mean follow-up of 5.1 years before a first ChEI dispensing, and 499 cases after ChEI initiation, during a mean follow-up of 2.0 years. Among the 2700 participants free of UI one year before ChEI initiation, the adjusted hazard ratio (HR) for UI was 1.13 (95% CI: 0.97-1.32) when periods with ChEI use were compared to periods without ChEI use. Sensitivity analyses may suggest an increased risk in the 1(st) month after ChEI initiation (HR: 1.72, p = 0.09) CONCLUSION: Worsening AD may increase incidence of UI, but no firm association between ChEI treatment and risk of UI could be shown from these data.

show abstract

“…Everyone registered with the NHS Tayside is allocated a unique identifying number, the Community Health Index number, which is the key to linking each person's health records from general practices, pharmacies, biochemistry laboratories, and hospitals to improve quality and promote research while preserving confidentiality. 17…”

Section: Data Sourcementioning

confidence: 99%

“…The HIC collects data on dispensed prescriptions from community pharmacies and links them to the Community Health Index number. 17 We used the pharmacy records to identify the timing, potency, and dosage of topical corticosteroids dispensed.…”

Section: Ascertainment Of Exposurementioning

confidence: 99%